Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Closes $400M Note Sale After Adding $50M Over-Allotment

NEW YORK (GenomeWeb News) — Illumina today said it has closed the sale of $400 million in convertible senior notes.
 
The company on Monday said it would sell $325 million in notes to pay for corporate expenses, but on Tuesday it raised the offering to $350 million.
 
The sale at closing included the exercise of an over-allotment for an additional $50 million of notes, bringing the total to $400 million.  
 
The sale will pay interest at .625 percent and will be due in 2014, at which time holders will receive cash value for the principal and common stock for any excess value.
 
Illumina said it plans to use $200 million from the sale to buy shares of its common stock in a private deal.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more